The aim of this study is to systematically review the available evidence on compound EGFR mutations in NSCLC, with regard to prevalence, distribution and efficacy of EGFR TKI treatments, in order to provide consistent information to support treatment selection in this particularly heterogeneous subgroup of patients. Here, EGFR is linked to non-small cell lung carcinoma.